Ann: Opthea Half Year Report and Accounts, page-6

.From the report, Co formulation a key for Opthea and will ultimately lead to OPT owning a new patent

. "The proceeds of the financing will primarily be used to
progress OPT-302 into the Phase 3 clinical program and to
develop a co-formulation of OPT-302 with a biosimilar antiVEGF-A therapy. We believe that a co-formulated OPT-302
and VEGF-A inhibitor product has the potential to be a marketleading treatment for wet AMD that offers the convenience
of a single-injection to achieve broader inhibition of the VEGF
signalling pathway, including VEGF-A, VEGF-C and VEGF-D."